Evaluate the Safety and Efficacy of Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered With Adjuvant AS01B

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

June 30, 2009

Conditions
Malaria
Interventions
BIOLOGICAL

Plasmodium falciparum Malaria Protein 010 (FMP010)

Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK

BIOLOGICAL

Rabipur

Rabipur is a licensed rabies vaccine.

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

United States Agency for International Development (USAID)

FED

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

collaborator

Kenya Medical Research Institute

OTHER

lead

U.S. Army Medical Research and Development Command

FED